INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14401, 27945, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14402, 28761, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14403, 28762, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14404, 28763, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14405, 28764, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14406, 33367, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14407, 33368, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14408, 33369, 'Paclitaxel (protein-bound)', 'Liver Diseases', 'Paclitaxel is extensively metabolized by the liver.  Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity.  Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN.  Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14409, 4454, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14410, 4455, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14411, 4457, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14412, 5419, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14413, 6347, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14414, 6352, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14415, 6353, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14416, 9544, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14417, 9545, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14418, 9554, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14419, 11212, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14420, 14273, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14421, 14274, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14422, 14275, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14423, 19674, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14424, 20879, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14425, 20880, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14426, 20881, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14427, 20882, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14428, 24438, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14429, 24440, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14430, 24441, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14431, 24442, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14432, 24443, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14433, 24445, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14434, 24446, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14435, 24447, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14436, 24448, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14437, 24460, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14438, 24461, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14439, 27945, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14440, 28761, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14441, 28762, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14442, 28763, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14443, 28764, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14444, 33367, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14445, 33368, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14446, 33369, 'Paclitaxel (protein-bound)', 'Bone Marrow Failure Disorders', 'Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils.  Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel.  Thrombocytopenia is uncommon and rarely severe.  Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3.  Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi''s sarcoma with baseline neutrophil counts of less than 1000/mm3.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14447, 4454, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14448, 4455, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14449, 4457, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14450, 5419, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14451, 6347, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14452, 6352, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14453, 6353, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14454, 9544, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14455, 9545, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14456, 9554, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14457, 11212, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14458, 14273, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14459, 14274, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14460, 14275, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14461, 19674, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14462, 20879, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14463, 20880, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14464, 20881, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14465, 20882, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14466, 24438, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14467, 24440, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14468, 24441, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14469, 24442, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14470, 24443, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14471, 24445, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14472, 24446, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14473, 24447, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14474, 24448, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14475, 24460, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14476, 24461, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14477, 27945, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14478, 28761, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14479, 28762, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14480, 28763, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14481, 28764, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14482, 33367, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14483, 33368, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14484, 33369, 'Paclitaxel (protein-bound)', 'Peripheral Nervous System Diseases', 'Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy.  Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel.  Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14485, 151, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14486, 11330, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14487, 11336, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14488, 11338, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14489, 11339, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14490, 11340, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14491, 27721, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14492, 28086, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14493, 28087, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14494, 28088, 'Oxytetracycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14495, 151, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14496, 11330, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14497, 11336, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14498, 11338, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14499, 11339, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (14500, 11340, 'Oxytetracycline', 'Diseases requiring hemodialysis', 'Oxytetracycline is partially removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
